Q3 EPS Estimate for NRx Pharmaceuticals Decreased by Analyst

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Analysts at HC Wainwright decreased their Q3 2026 earnings estimates for shares of NRx Pharmaceuticals in a research note issued on Tuesday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.03 for the quarter, down from their prior forecast of $0.04. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2030 earnings at $6.15 EPS.

A number of other equities analysts have also issued reports on the company. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. BTIG Research reaffirmed a “buy” rating and set a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, February 17th. Finally, Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, NRx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $1.77 on Wednesday. The firm has a market cap of $56.41 million, a P/E ratio of -0.75 and a beta of 1.97. NRx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $3.84. The firm’s 50-day simple moving average is $2.10 and its 200-day simple moving average is $2.50.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently modified their holdings of the business. Ethos Financial Group LLC bought a new position in shares of NRx Pharmaceuticals during the 3rd quarter valued at about $39,000. Sjbenen Advisory LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter worth approximately $41,000. One Wealth Management Investment & Advisory Services LLC raised its holdings in NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares during the period. Global Retirement Partners LLC bought a new position in NRx Pharmaceuticals in the fourth quarter valued at approximately $107,000. Finally, Two Sigma Investments LP lifted its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares in the last quarter. 4.27% of the stock is currently owned by institutional investors.

Trending Headlines about NRx Pharmaceuticals

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright sharply raised multi-year EPS forecasts and reiterated a Buy rating with a $45 price target, projecting material earnings growth from FY2026 through FY2029 (Q4‑2026: $0.06; FY2026: $0.13; FY2027: $1.23; FY2028: $3.18; FY2029: $5.06). This signals that at least one boutique analyst expects a strong recovery and significant upside vs. the current share price. HC Wainwright Forecasts Strong Price Appreciation for NRx Pharmaceuticals (NASDAQ:NRXP) Stock
• Neutral Sentiment: Zacks Research moved NRXP from “strong sell” to “hold,” reducing one source of bearish pressure but not endorsing a buy — a modest signal that downside may be stabilizing but not yet reversed. Zacks upgrade coverage (TickerReport)
• Negative Sentiment: HC Wainwright trimmed its Q3‑2026 EPS estimate (from $0.04 to $0.03), a near-term downgrade that tempers some of the upbeat multi-year outlook and highlights potential short-term execution or timing risk. MarketBeat NRXP coverage (analyst notes)
• Negative Sentiment: Consensus still shows a current full-year loss (consensus ~($1.75) EPS), so HC Wainwright’s optimistic projections are aggressive and depend on successful product/commercial execution and milestone delivery; failure to meet milestones would keep downside risk elevated. MarketBeat NRXP consensus data

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.